6.32
-0.14 (-2.17%)
| Previous Close | 6.46 |
| Open | 6.34 |
| Volume | 639,657 |
| Avg. Volume (3M) | 1,338,053 |
| Market Cap | 343,035,712 |
| Price / Earnings (Forward) | 44.05 |
| Price / Sales | 0.390 |
| Price / Book | 0.650 |
| 52 Weeks Range | |
| Earnings Date | 11 Aug 2025 |
| Profit Margin | -13.63% |
| Operating Margin (TTM) | 22.68% |
| Diluted EPS (TTM) | -2.58 |
| Quarterly Revenue Growth (YOY) | -26.00% |
| Quarterly Earnings Growth (YOY) | 655.60% |
| Total Debt/Equity (MRQ) | 121.71% |
| Current Ratio (MRQ) | 6.32 |
| Operating Cash Flow (TTM) | 110.10 M |
| Levered Free Cash Flow (TTM) | 91.12 M |
| Return on Assets (TTM) | -1.61% |
| Return on Equity (TTM) | -21.63% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Bearish | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Bearish | Mixed | |
| Stock | Emergent BioSolutions Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 0.50 |
|
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company operates across three different segments, namely Commercial, Products, and Services. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Value |
| % Held by Insiders | 2.83% |
| % Held by Institutions | 67.21% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Oak Hill Advisors Lp | 31 Mar 2025 | 1,113,338 |
| 52 Weeks Range | ||
| Median | 15.00 (137.34%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 01 Apr 2025 | 15.00 (137.34%) | Buy | 4.74 |
| 21 Mar 2025 | 15.00 (137.34%) | Buy | 5.72 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |